CN100488511C - 化合物及其在制备治疗良性前列腺增生及相关症状的药物中的应用 - Google Patents

化合物及其在制备治疗良性前列腺增生及相关症状的药物中的应用 Download PDF

Info

Publication number
CN100488511C
CN100488511C CNB2004100800817A CN200410080081A CN100488511C CN 100488511 C CN100488511 C CN 100488511C CN B2004100800817 A CNB2004100800817 A CN B2004100800817A CN 200410080081 A CN200410080081 A CN 200410080081A CN 100488511 C CN100488511 C CN 100488511C
Authority
CN
China
Prior art keywords
compound
purposes
benign prostatic
prostatic hyperplasia
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2004100800817A
Other languages
English (en)
Chinese (zh)
Other versions
CN1615891A (zh
Inventor
L·阿多里尼
E·科利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioxell SpA
Original Assignee
Bioxell SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0322395A external-priority patent/GB0322395D0/en
Priority claimed from GB0325598A external-priority patent/GB2407499B/en
Priority claimed from GB0416876A external-priority patent/GB0416876D0/en
Application filed by Bioxell SpA filed Critical Bioxell SpA
Publication of CN1615891A publication Critical patent/CN1615891A/zh
Application granted granted Critical
Publication of CN100488511C publication Critical patent/CN100488511C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CNB2004100800817A 2003-09-24 2004-09-24 化合物及其在制备治疗良性前列腺增生及相关症状的药物中的应用 Expired - Fee Related CN100488511C (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0322395.5 2003-09-24
GB0322395A GB0322395D0 (en) 2003-09-24 2003-09-24 Methods for treating bladder dysfunction and related compounds and compositions
GB0325598A GB2407499B (en) 2003-11-03 2003-11-03 Vitamin D3 analogue for use in the treatment of BPH
GB0325598.1 2003-11-03
GB0416876.1 2004-07-29
GB0416876A GB0416876D0 (en) 2004-07-29 2004-07-29 Compound and use in treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2008102125148A Division CN101352446A (zh) 2003-09-24 2004-09-24 化合物及其在治疗良性前列腺增生及相关症状中的应用

Publications (2)

Publication Number Publication Date
CN1615891A CN1615891A (zh) 2005-05-18
CN100488511C true CN100488511C (zh) 2009-05-20

Family

ID=34229055

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004100800817A Expired - Fee Related CN100488511C (zh) 2003-09-24 2004-09-24 化合物及其在制备治疗良性前列腺增生及相关症状的药物中的应用

Country Status (11)

Country Link
EP (1) EP1673096A1 (https=)
JP (2) JP2007506699A (https=)
CN (1) CN100488511C (https=)
BE (1) BE1016292A3 (https=)
BR (1) BRPI0404050A (https=)
CH (1) CH698144B1 (https=)
EA (1) EA010240B1 (https=)
FR (1) FR2859910B1 (https=)
NL (1) NL1027109C2 (https=)
NZ (1) NZ535531A (https=)
WO (1) WO2005027923A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110494149A (zh) * 2017-03-20 2019-11-22 皮埃尔法布雷医药公司 香脂树属油树脂在前列腺病变中的用途

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090227651A1 (en) * 2004-10-05 2009-09-10 Kissei Pharmaceutical Co., Ltd. Preventive and/or therapeutic agent for urine collection disorder accompanying lower urinary tract obstruction
PL1806136T3 (pl) * 2004-10-06 2012-04-30 Kissei Pharmaceutical Kompozycja medyczna do zapobiegania przejściu na leczenie operacyjne łagodnego rozrostu gruczołu krokowego
US20100009949A1 (en) * 2006-03-24 2010-01-14 Bioxell S.P.A. Novel method
US8221803B1 (en) 2007-06-25 2012-07-17 OncoNatural Solutions, Inc. Composition for prostate health
US20120164240A1 (en) 2010-12-22 2012-06-28 Audino David Lawrence Enriched a. blitoides compositions and uses thereof
US20170049834A1 (en) * 2015-08-18 2017-02-23 Golden Biotechnology Corporation Benign prostatic hyperplasia add-on therapy
CN120960385A (zh) * 2025-08-01 2025-11-18 上海交通大学医学院附属第九人民医院 5α–还原酶降解分子及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0808833A2 (en) * 1996-05-23 1997-11-26 F. Hoffmann-La Roche Ag Vitamin D3 analogs
WO1998029123A1 (en) * 1996-12-30 1998-07-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin d analogues
WO2003034961A1 (en) * 2001-10-23 2003-05-01 Euro-Celtique, S.A. Terazosin transdermal device and methods
WO2003047595A1 (en) * 2001-12-03 2003-06-12 Novacea, Inc. Pharmaceutical compositions comprising active vitamin d compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW403735B (en) * 1995-11-22 2000-09-01 Hoffmann La Roche 25-hydroxy-16-ene-26, 27-bishomo-cholecalciferol
CA2289209C (en) * 1997-05-16 2006-07-25 Women & Infants Hospital Cyclic ether vitamin d3 compounds, 1.alpha. (oh) 3-epi-vitamin d3 compounds and uses thereof
US5872113A (en) * 1997-05-16 1999-02-16 Syntex (U.S.A.) Inc. Fluorinated vitamin D3 analogs
US6255501B1 (en) * 1999-04-26 2001-07-03 Hoffman-La Roche Inc. Process for preparing antiosteoporotic agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0808833A2 (en) * 1996-05-23 1997-11-26 F. Hoffmann-La Roche Ag Vitamin D3 analogs
WO1998029123A1 (en) * 1996-12-30 1998-07-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin d analogues
WO2003034961A1 (en) * 2001-10-23 2003-05-01 Euro-Celtique, S.A. Terazosin transdermal device and methods
WO2003047595A1 (en) * 2001-12-03 2003-06-12 Novacea, Inc. Pharmaceutical compositions comprising active vitamin d compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BioXell commences phase II trial of BXL-628. ANON.DRUG NEWS & PERSPECTIVES,Vol.16 No.2. 2003 *
BXL-628. MEALY N E.DRUGS OF THE FUTURE 2004 SPAIN,Vol.29 No.6. 2004 *
Chemical reactivity of Ro-26-9228,1alpha-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholecalciferol in aqueous solution. BRANDL MICHAEL ET AL.JOURNAL OF PHARMACEUTICAL SCIENCES,Vol.92 No.10. 2003 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110494149A (zh) * 2017-03-20 2019-11-22 皮埃尔法布雷医药公司 香脂树属油树脂在前列腺病变中的用途

Also Published As

Publication number Publication date
BE1016292A3 (nl) 2006-07-04
EA010240B1 (ru) 2008-06-30
EP1673096A1 (en) 2006-06-28
NZ535531A (en) 2006-03-31
NL1027109A1 (nl) 2005-03-29
BRPI0404050A (pt) 2005-06-14
WO2005027923A1 (en) 2005-03-31
NL1027109C2 (nl) 2005-05-03
CN1615891A (zh) 2005-05-18
FR2859910B1 (fr) 2006-04-28
JP2007506699A (ja) 2007-03-22
EA200401100A1 (ru) 2005-04-28
JP2009035559A (ja) 2009-02-19
HK1085373A1 (zh) 2006-08-25
CH698144B1 (fr) 2009-05-29
FR2859910A1 (fr) 2005-03-25

Similar Documents

Publication Publication Date Title
US20080207769A1 (en) Method for treating benign prostatic hyperplasia
TWI477276B (zh) 抗黃體素給藥方案
ES2643318T3 (es) Composiciones y métodos para suprimir la proliferación endometrial
Drobac et al. A workshop on pubertal hormone replacement options in the United States
JP2009035559A (ja) 良性前立腺肥大の治療のためのビタミンｄ３アナログの使用
Tartagni et al. Intermittent low-dose finasteride administration is effective for treatment of hirsutism in adolescent girls: a pilot study
Gkionia et al. Androgens in menopausal women: not only polycystic ovary syndrome
US20060063723A1 (en) Pharmaceutical composition comprising esterol derivatives for use in cancer therapy
KR20090119870A (ko) 자궁내막증 치료를 위한 미네랄코르티코이드 수용체 길항제
CN101352446A (zh) 化合物及其在治疗良性前列腺增生及相关症状中的应用
HK1085373B (en) Compound and use in the manufacture of a medicament for the treatment of benign prostatic hyperplasia and associated symptoms
JP2021519799A (ja) 物質離脱障害を治療するためのｇａｂａ−ａアンタゴニスト
GB2407499A (en) Compound and use in treatment
Clapauch et al. Testosterone and women
TW200927137A (en) Compositions and methods for treating dysfunctional uterine bleeding
EP1303270B1 (en) Method for treating cryptorchidism
EP3269373A1 (en) Low-dosed oral dosage form of an akr1c3 inhibitor for treatment of diseases
Rasmusson et al. Merck Research Laboratories, Rahway, NJ 07065
Mawet Estetrol (E4), the Fourth Natural Estrogen, Molecular and Clinical Aspects
WO2022115581A1 (en) Methods for treating infertility and/or endometriosis comprising ex-527
US20190269686A1 (en) Compositions and methods for the treatment of endometriosis
Yapura Development of a non-steroidal aromatase inhibitor-based protocol for the control of ovarian function using a bovine model
Legro 11 Polycystic Ovary Syndrome
Yahya Abdelrahman et al. Polycystic ovary syndrome in adolescents
Lakshmi Prevalence of Obesity, Hyperglycemia and Hypertriglyceridemia in Women with Polycystic Ovarian Syndrome

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1085373

Country of ref document: HK

C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1085373

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090520

Termination date: 20100924